Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Agranulocytosis due to deferiprone: a case report with cytomorphological and functional bone marrow examination.

Masera N, Tavecchia L, Longoni DV, Maglia O, Biondi A, Masera G.

Blood Transfus. 2011 Oct;9(4):462-5. doi: 10.2450/2011.0098-10. Epub 2011 Jul 18. No abstract available.

2.

GH deficiency in adult B-thalassemia major patients and its relationship with IGF-1 production.

Pincelli AI, Masera N, Tavecchia L, Perotti M, Perra S, Mariani R, Piperno A, Mancia G, Grassi G, Masera G.

Pediatr Endocrinol Rev. 2011 Mar;8 Suppl 2:284-9.

PMID:
21705979
3.

Optimal response to thalidomide in a patient with thalassaemia major resistant to conventional therapy.

Masera N, Tavecchia L, Capra M, Cazzaniga G, Vimercati C, Pozzi L, Biondi A, Masera G.

Blood Transfus. 2010 Jan;8(1):63-5. doi: 10.2450/2009.0102-09. No abstract available.

4.

Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions.

Perseghin P, Terruzzi E, Dassi M, Baldini V, Parma M, Coluccia P, Accorsi P, Confalonieri G, Tavecchia L, Verga L, Ravagnani F, Iacone A, Pogliani EM, Pioltelli P.

Transfus Apher Sci. 2009 Aug;41(1):33-7. doi: 10.1016/j.transci.2009.05.011. Epub 2009 Jun 18.

PMID:
19540167
5.

Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox (ICL670) at the Pediatric Clinic in Monza, Italy.

Masera N, Rescaldani C, Azzolini M, Vimercati C, Tavecchia L, Masera G, De Molfetta V, Arpa P.

Haematologica. 2008 Jan;93(1):e9-10. doi: 10.3324/haematol.11782. No abstract available.

6.

Periodic erythroexchange is an effective strategy for high risk paediatric patients with sickle-cell disease.

Masera N, Tavecchia L, Pozzi L, Riva F, Vimercati C, Calabria M, Ronzoni S, Masera G, Perseghin P.

Transfus Apher Sci. 2007 Dec;37(3):241-7. Epub 2007 Nov 26.

PMID:
18042436
7.

Successful recovery of acute hemosiderotic heart failure in beta-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone.

Tavecchia L, Masera N, Russo P, Cirò A, Vincenzi A, Vimercati C, Masera G.

Haematologica. 2006 Jun;91(6 Suppl):ECR19.

8.

Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance.

Gobbi PG, Ghirardelli ML, Solcia M, Di Giulio G, Merli F, Tavecchia L, Bertè R, Davini O, Levis A, Broglia C, Maffè GC, Ilariucci F, Dore R, Ascari E.

J Clin Oncol. 2001 Mar 1;19(5):1388-94.

PMID:
11230483
9.

Intracellular cytokine profile of cord blood T-, and NK- cells and monocytes.

Krampera M, Tavecchia L, Benedetti F, Nadali G, Pizzolo G.

Haematologica. 2000 Jul;85(7):675-9.

10.
11.

Regulation of the proliferative potential of cord blood long-term culture-initiating cells (LTC-IC) by different stromal cell lines: implications for LTC-IC measurement.

Nadali G, de Wynter EA, Perandin F, Tavecchia L, Vincenzi C, Ambrosetti A, Fornalè M, Perona G, Pizzolo G, Testa NG.

Haematologica. 1998 Dec;83(12):1059-65.

12.

Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome.

Nadali G, Tavecchia L, Zanolin E, Bonfante V, Viviani S, Camerini E, Musto P, Di Renzo N, Carotenuto M, Chilosi M, Krampera M, Pizzolo G.

Blood. 1998 Apr 15;91(8):3011-6.

Supplemental Content

Loading ...
Support Center